Eradicating suicide at its roots: Preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors

Domenico De Berardis, Michele Fornaro, Alessandro Valchera, Marilde Cavuto, Giampaolo Perna, Marco Di Nicola, Gianluca Serafini, Alessandro Carano, Maurizio Pompili, Federica Vellante, Laura Orsolini, Annastasia Fiengo, Antonio Ventriglio, Yong Ku Kim, Giovanni Martinotti, Massimo Di Giannantonio, Carmine Tomasetti

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Despite the continuous advancement in neurosciences as well as in the knowledge of human behaviors pathophysiology, currently suicide represents a puzzling challenge. The World Health Organization (WHO) has established that one million people die by suicide every year, with the impressive daily rate of a suicide every 40 s. The weightiest concern about suicidal behavior is how difficult it is for healthcare professionals to predict. However, recent evidence in genomic studies has pointed out the essential role that genetics could play in influencing person’s suicide risk. Combining genomic and clinical risk assessment approaches, some studies have identified a number of biomarkers for suicidal ideation, which are involved in neural connectivity, neural activity, mood, as well as in immune and inflammatory response, such as the mammalian target of rapamycin (mTOR) signaling. This interesting discovery provides the neurobiological bases for the use of drugs that impact these specific signaling pathways in the treatment of suicidality, such as ketamine. Ketamine, an N-methyl-d-aspartate glutamate (NMDA) antagonist agent, has recently hit the headlines because of its rapid antidepressant and concurrent anti-suicidal action. Here we review the preclinical and clinical evidence that lay the foundations of the efficacy of ketamine in the treatment of suicidal ideation in mood disorders, thereby also approaching the essential question of the understanding of neurobiological processes of suicide and the potential therapeutics.

Original languageEnglish
Article number2888
JournalInternational Journal of Molecular Sciences
Volume19
Issue number10
DOIs
Publication statusPublished - 2018 Oct 1

Fingerprint

moods
Ketamine
Suicide
human behavior
neurology
aspartates
glutamates
risk assessment
biomarkers
Biomarkers
Suicidal Ideation
Risk assessment
health
Excitatory Amino Acid Antagonists
drugs
Health
disorders
Sirolimus
Excitatory Amino Acid Agents
Aspartic Acid

Keywords

  • Antidepressants
  • Antipsychotics
  • Dopamine
  • Esketamine
  • Glutamate
  • Ketamine
  • Mood disorders
  • NMDA
  • Postsynaptic density
  • Serotonin
  • Suicide

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Eradicating suicide at its roots : Preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors. / De Berardis, Domenico; Fornaro, Michele; Valchera, Alessandro; Cavuto, Marilde; Perna, Giampaolo; Di Nicola, Marco; Serafini, Gianluca; Carano, Alessandro; Pompili, Maurizio; Vellante, Federica; Orsolini, Laura; Fiengo, Annastasia; Ventriglio, Antonio; Kim, Yong Ku; Martinotti, Giovanni; Di Giannantonio, Massimo; Tomasetti, Carmine.

In: International Journal of Molecular Sciences, Vol. 19, No. 10, 2888, 01.10.2018.

Research output: Contribution to journalReview article

De Berardis, D, Fornaro, M, Valchera, A, Cavuto, M, Perna, G, Di Nicola, M, Serafini, G, Carano, A, Pompili, M, Vellante, F, Orsolini, L, Fiengo, A, Ventriglio, A, Kim, YK, Martinotti, G, Di Giannantonio, M & Tomasetti, C 2018, 'Eradicating suicide at its roots: Preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors', International Journal of Molecular Sciences, vol. 19, no. 10, 2888. https://doi.org/10.3390/ijms19102888
De Berardis, Domenico ; Fornaro, Michele ; Valchera, Alessandro ; Cavuto, Marilde ; Perna, Giampaolo ; Di Nicola, Marco ; Serafini, Gianluca ; Carano, Alessandro ; Pompili, Maurizio ; Vellante, Federica ; Orsolini, Laura ; Fiengo, Annastasia ; Ventriglio, Antonio ; Kim, Yong Ku ; Martinotti, Giovanni ; Di Giannantonio, Massimo ; Tomasetti, Carmine. / Eradicating suicide at its roots : Preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors. In: International Journal of Molecular Sciences. 2018 ; Vol. 19, No. 10.
@article{3900f11a6c11412e9d856e58053c72e8,
title = "Eradicating suicide at its roots: Preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors",
abstract = "Despite the continuous advancement in neurosciences as well as in the knowledge of human behaviors pathophysiology, currently suicide represents a puzzling challenge. The World Health Organization (WHO) has established that one million people die by suicide every year, with the impressive daily rate of a suicide every 40 s. The weightiest concern about suicidal behavior is how difficult it is for healthcare professionals to predict. However, recent evidence in genomic studies has pointed out the essential role that genetics could play in influencing person’s suicide risk. Combining genomic and clinical risk assessment approaches, some studies have identified a number of biomarkers for suicidal ideation, which are involved in neural connectivity, neural activity, mood, as well as in immune and inflammatory response, such as the mammalian target of rapamycin (mTOR) signaling. This interesting discovery provides the neurobiological bases for the use of drugs that impact these specific signaling pathways in the treatment of suicidality, such as ketamine. Ketamine, an N-methyl-d-aspartate glutamate (NMDA) antagonist agent, has recently hit the headlines because of its rapid antidepressant and concurrent anti-suicidal action. Here we review the preclinical and clinical evidence that lay the foundations of the efficacy of ketamine in the treatment of suicidal ideation in mood disorders, thereby also approaching the essential question of the understanding of neurobiological processes of suicide and the potential therapeutics.",
keywords = "Antidepressants, Antipsychotics, Dopamine, Esketamine, Glutamate, Ketamine, Mood disorders, NMDA, Postsynaptic density, Serotonin, Suicide",
author = "{De Berardis}, Domenico and Michele Fornaro and Alessandro Valchera and Marilde Cavuto and Giampaolo Perna and {Di Nicola}, Marco and Gianluca Serafini and Alessandro Carano and Maurizio Pompili and Federica Vellante and Laura Orsolini and Annastasia Fiengo and Antonio Ventriglio and Kim, {Yong Ku} and Giovanni Martinotti and {Di Giannantonio}, Massimo and Carmine Tomasetti",
year = "2018",
month = "10",
day = "1",
doi = "10.3390/ijms19102888",
language = "English",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "10",

}

TY - JOUR

T1 - Eradicating suicide at its roots

T2 - Preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors

AU - De Berardis, Domenico

AU - Fornaro, Michele

AU - Valchera, Alessandro

AU - Cavuto, Marilde

AU - Perna, Giampaolo

AU - Di Nicola, Marco

AU - Serafini, Gianluca

AU - Carano, Alessandro

AU - Pompili, Maurizio

AU - Vellante, Federica

AU - Orsolini, Laura

AU - Fiengo, Annastasia

AU - Ventriglio, Antonio

AU - Kim, Yong Ku

AU - Martinotti, Giovanni

AU - Di Giannantonio, Massimo

AU - Tomasetti, Carmine

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Despite the continuous advancement in neurosciences as well as in the knowledge of human behaviors pathophysiology, currently suicide represents a puzzling challenge. The World Health Organization (WHO) has established that one million people die by suicide every year, with the impressive daily rate of a suicide every 40 s. The weightiest concern about suicidal behavior is how difficult it is for healthcare professionals to predict. However, recent evidence in genomic studies has pointed out the essential role that genetics could play in influencing person’s suicide risk. Combining genomic and clinical risk assessment approaches, some studies have identified a number of biomarkers for suicidal ideation, which are involved in neural connectivity, neural activity, mood, as well as in immune and inflammatory response, such as the mammalian target of rapamycin (mTOR) signaling. This interesting discovery provides the neurobiological bases for the use of drugs that impact these specific signaling pathways in the treatment of suicidality, such as ketamine. Ketamine, an N-methyl-d-aspartate glutamate (NMDA) antagonist agent, has recently hit the headlines because of its rapid antidepressant and concurrent anti-suicidal action. Here we review the preclinical and clinical evidence that lay the foundations of the efficacy of ketamine in the treatment of suicidal ideation in mood disorders, thereby also approaching the essential question of the understanding of neurobiological processes of suicide and the potential therapeutics.

AB - Despite the continuous advancement in neurosciences as well as in the knowledge of human behaviors pathophysiology, currently suicide represents a puzzling challenge. The World Health Organization (WHO) has established that one million people die by suicide every year, with the impressive daily rate of a suicide every 40 s. The weightiest concern about suicidal behavior is how difficult it is for healthcare professionals to predict. However, recent evidence in genomic studies has pointed out the essential role that genetics could play in influencing person’s suicide risk. Combining genomic and clinical risk assessment approaches, some studies have identified a number of biomarkers for suicidal ideation, which are involved in neural connectivity, neural activity, mood, as well as in immune and inflammatory response, such as the mammalian target of rapamycin (mTOR) signaling. This interesting discovery provides the neurobiological bases for the use of drugs that impact these specific signaling pathways in the treatment of suicidality, such as ketamine. Ketamine, an N-methyl-d-aspartate glutamate (NMDA) antagonist agent, has recently hit the headlines because of its rapid antidepressant and concurrent anti-suicidal action. Here we review the preclinical and clinical evidence that lay the foundations of the efficacy of ketamine in the treatment of suicidal ideation in mood disorders, thereby also approaching the essential question of the understanding of neurobiological processes of suicide and the potential therapeutics.

KW - Antidepressants

KW - Antipsychotics

KW - Dopamine

KW - Esketamine

KW - Glutamate

KW - Ketamine

KW - Mood disorders

KW - NMDA

KW - Postsynaptic density

KW - Serotonin

KW - Suicide

UR - http://www.scopus.com/inward/record.url?scp=85053833014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053833014&partnerID=8YFLogxK

U2 - 10.3390/ijms19102888

DO - 10.3390/ijms19102888

M3 - Review article

C2 - 30249029

AN - SCOPUS:85053833014

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 10

M1 - 2888

ER -